- Date: November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund. GlyCardial is a spin-off from the Catalan Institute of Cardiovascular Sciences (ICCC), which participated in CaixaImpulse 2015 through the Apo J-Glyc project.
The project was named after the protein identified by the ICCC team as a biomarker for early myocardial ischemia diagnosis, and, as in most heart conditions, quick detection is crucial when treating the disease. Caused by a lack of blood supply in the heart, myocardial ischemia is the most common cardiovascular issue, and if it becomes persistent it can end up causing a heart attack.
Led by Judit Cubedo (CEO) and Lina Badimon (CSO), GlyCardial Diagnostics aims to develop a point-of-care device that can quickly detect abnormal levels of Apo J-Glyc protein in the blood. This device could be used in ambulances for example, and would provide an accurate test to allow healthcare decisions to be made quickly. The funds will allow the company to clinically validate the new blood test and to apply for the CE certification mark over the next three years, which would allow the device to be sold in the European Economic Area.
More programme highlights
December 13, 2018
The Financing Week marks the end of the training sessions for leaders of the projects chosen for this year's CaixaImpulse programme.
October 31, 2018
From 6 to 9 November, the leaders of the projects selected to take part in CaixaImpulse 2018 have a date with the third week of training sessions offered under the programme.
October 11, 2018
Led by a number of different experts, this training focuses on product development and intellectual property.